Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered As a 3-dose Regimen in Healthy Young Adults Aged ≥18 to <26 Years

Next Previous
Trial Profile

A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered As a 3-dose Regimen in Healthy Young Adults Aged ≥18 to <26 Years

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine group B (Primary)
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Pfizer

Most Recent Events

  • 14 Dec 2017 Pooled results from this and another phase III study, published in the New England Journal of Medicine.
  • 30 May 2017 According to a Pfizer media release, the European Commission (EC) has approved TRUMENBA (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older. Results from this study supported the approval.
  • 13 May 2016 The results from this an another phase III trial (see CT profile 700208966) support additional upcoming global regulatory submissions and the planned US supplement to request the conversion of Accelerated Approval to Traditional Approval for TRUMENBA, according to a Pfizer media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top